On Oct.25th, 2021, Shanghai SunBio Co., Ltd. (hereafter SunBio for short) and Shanghai Runda Medical Technology Co., Ltd. (hereafter Runda Medical for short) officially signed a strategic cooperation agreement. Mr. Hai Qing the CEO of SunBio, Mr. Xie Yongxin the Deputy General Manager of Sunbio and Mr. Liu Hui the General Manager of Runda Medical, Mr. Hu Zhenning the Deputy General Manager are present at the meeting.

SunBio is the leading enterprise of the domestic thrombosis and hemostasis diagnosis industry subdivision, has focused on this field for over 20 years, successfully developed a series of coagulation diagnostic reagents, thrombosis and hemostasis diagnostic reagents, automatic coagulation analyzer and medical consumables etc. more than 100 products, forming SunBio built-in detection system, and reagents are compatible for the mainstream brand coagulation analyzer on the market, establishing the reagent-instruments- consumables complete product chain, with many medical university affiliated hospitals, provincial hospital users. The technical level of the products is in the leading position in the industry
Mr. Hai Qing, Sunbio CEO addressed SunBio pursues to meet customer needs with excellent performance, at the same time keeping quality control firmly in the forefront, look forward to both sides respective advantages, following the health care reform, In the environment of both opportunities and challenges brought hierarchical diagnosis treatment and centralized procurement, pushing localization of blood coagulation products to a new height.
As a leading enterprise of hospital laboratory delicacy management service, Runda Medical’s Intensive, regional testing center business has grown rapidly in recent years. Up to now, there are nearly 400 signed clilents which makes Runda the enterprise with the most intensive customers in China. Meanwhile, as a hospital laboratory comprehensive service platform enterprise, Runda Medical has served more than 4,000 customers for a long time. Mr. Liu Hui General Manager of Runda medical addressed Runda medical has focused on IVD industry, and has established good cooperation with many domestic and foreign mainstream brands. This is not only for Runda's unremitting efforts, but also the inevitable result of mutual trust and benefit between partners. The policy trend of localization policy provides broad development space for the cooperation of coagulation business between Runda Medical and SunBio. We hope both sides will further deepen cooperation and achieve win-win results.
The signing of this strategic cooperation is the result of both SunBio and Runda Medical based on the judgment of the market and the recognition of both sides’ capabilities. This cooperation not only realizes the complementary advantages and resource sharing of the enterprises on both sides, but also actively responds to the national localization policy of medical devices, and provides a beneficial exploration for improving the production level of domestic IVD R &D.
Both sides agreed that the signing of the strategic agreement is only the starting point of long-term cooperation. In the future, the two sides will steadily implement the cooperation content, ensure the stable growth of SunBio products and Runda medical business, and jointly write a new chapter in the localization of medical devices.